Kaplonek, Paulina;
Deng, Yixiang;
Shih-Lu Lee, Jessica;
Zar, Heather J;
Zavadska, Dace;
Johnson, Marina;
Lauffenburger, Douglas A;
... Alter, Galit; + view all
(2023)
Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines.
Cell Reports Medicine
, 4
(5)
, Article 101048. 10.1016/j.xcrm.2023.101048.
Preview |
Text
PIIS2666379123001623.pdf - Published Version Download (4MB) | Preview |
Abstract
Despite the successes of current coronavirus disease 2019 (COVID-19) vaccines, waning immunity, the emergence of variants of concern, and breakthrough infections among vaccinees have begun to highlight opportunities to improve vaccine platforms. Real-world vaccine efficacy studies have highlighted the reduced risk of breakthrough infections and diseases among individuals infected and vaccinated, referred to as hybrid immunity. Thus, we sought to define whether hybrid immunity shapes the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following Pfizer/BNT162b2, Moderna mRNA-1273, ChadOx1/AZD1222, and Ad26.COV2.S vaccination. Each vaccine exhibits a unique functional humoral profile in vaccination only or hybrid immunity. However, hybrid immunity shows a unique augmentation of S2-domain-specific functional immunity that was poorly induced for the vaccination only. These data highlight the importance of natural infection in breaking the immunodominance away from the evolutionarily unstable S1 domain and potentially affording enhanced cross-variant protection by targeting the more highly conserved S2 domain of SARS-CoV-2.
| Type: | Article |
|---|---|
| Title: | Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.xcrm.2023.101048 |
| Publisher version: | https://doi.org/10.1016/j.xcrm.2023.101048 |
| Language: | English |
| Additional information: | © 2023 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | COVID-19, FcR binding, SARS-CoV-2, VOCs, antibody, antibody functions, mRNA vaccine, vaccine, vector vaccine |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10170159 |
Archive Staff Only
 |
View Item |
